- Conditions
- Multiple Sclerosis (MS) Primary Progressive
- Interventions
- Orelabrutinib, Placebo
- Drug
- Lead sponsor
- Zenas BioPharma (USA), LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 705 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 19
- States / cities
- Pheonix, Arizona • Scottsdale, Arizona • West Hollywood, California + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- Orelabrutinib, Placebo
- Drug
- Lead sponsor
- Zenas BioPharma (USA), LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 990 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Fullerton, California + 22 more
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- placebo, orelabrutinib
- Other · Drug
- Lead sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 5
- States / cities
- Ormond Beach, Florida • Tampa, Florida • Northbrook, Illinois + 2 more
- Conditions
- Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies
- Interventions
- Orelabrutinib (ICP-022)
- Drug
- Lead sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Anaheim, California • Los Angeles, California + 24 more